ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0100338

urinary tract infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. urinary tract infection. Diseases, record MONDO_0100338. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100338

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
urinary tract infection
Open Targets
Open Targets ID
MONDO_0100338
Open Targets
Other names
INFECTION, URINARY TRACT, TRACT, INFECTION OF URINARY, urinary tract infection (disease)
Open Targets
Disease Ontology
DOID:0080784
Disease Ontology
MeSH
D014552
MeSH
Highest stage of its drugs
Approval, for 57 of its 104 drugs, from DailyMed, EMA Human Drugs, FDA and TTD
Open Targets

Drugs104

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
TRIMETHOPRIMCHEMBL22Small moleculeApprovalDailyMed, FDA and TTD9466Drugs and targets
NITROFURANTOINCHEMBL572Small moleculeApprovalDailyMed and TTD7666Drugs and targets
CIPROFLOXACINCHEMBL8Small moleculeApprovalDailyMed1655Drugs and targets
CEFTAZIDIMECHEMBL44354Small moleculeApprovalDailyMed and EMA Human Drugs755Drugs and targets
CEFEPIMECHEMBL186Small moleculeApprovalEMA Human Drugs655Drugs and targets
LEVOFLOXACINCHEMBL5315124Small moleculeApprovalDailyMed8344Drugs and targets
MEROPENEMCHEMBL127Small moleculeApprovalEMA Human Drugs, FDA and TTD744Drugs and targets
AVIBACTAMCHEMBL1689063Small moleculeApprovalEMA Human Drugs644Drugs and targets
AMOXICILLINCHEMBL1082Small moleculeApprovalDailyMed544Drugs and targets
IMIPENEMCHEMBL43708Small moleculeApprovalDailyMed1133Drugs and targets

1 to 10 of 104

See all 104 drugs

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRA1AAdrenergic receptor alpha-12Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonistPhase 3https://conductscience.org/library/genes/148Drugs and targets
ADRA1BAdrenergic receptor alpha-12Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonistPhase 3https://conductscience.org/library/genes/147Drugs and targets
ADRA1DAdrenergic receptor alpha-12Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonistPhase 3https://conductscience.org/library/genes/146Drugs and targets
DPEP1Dipeptidase 12Renal dipeptidase inhibitorApprovalhttps://conductscience.org/library/genes/1800Drugs and targets
SLC5A2Sodium/glucose cotransporter 22Sodium/glucose cotransporter 2 inhibitorUnknownhttps://conductscience.org/library/genes/6524Drugs and targets
DPP4Dipeptidyl peptidase 41Dipeptidyl peptidase IV inhibitorUnknownhttps://conductscience.org/library/genes/1803Drugs and targets
ESR1Estrogen receptor1Estrogen receptor alpha agonistUnknownhttps://conductscience.org/library/genes/2099Drugs and targets
NR3C1Glucocorticoid receptor1Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
PDE4APhosphodiesterase 41Phosphodiesterase 4 inhibitorApprovalhttps://conductscience.org/library/genes/5141Drugs and targets
PDE4BPhosphodiesterase 41Phosphodiesterase 4 inhibitorApprovalhttps://conductscience.org/library/genes/5142Drugs and targets

1 to 10 of 17

See all 17 targets

Trials74

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01426191Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection2,0322019-10-04Respiratory Tract Infections, Urinary Tract InfectionsCEFOTAXIME SODIUM, SULBACTAM SODIUMIts record names the diseaseClinicalTrials.gov
NCT04187144Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)Phase 31,6062023-07-18Urinary Tract InfectionsGEPOTIDACIN, NITROFURANTOINIts record names the diseaseClinicalTrials.gov
NCT04020341A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)Phase 31,5312023-06-22Urinary Tract InfectionsGEPOTIDACIN, NITROFURANTOINIts record names the diseaseClinicalTrials.gov
NCT03788967
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase 31,3722022-07-25Complicated Urinary Tract Infection, Acute PyelonephritisERTAPENEM, TEBIPENEM PIVOXIL HYDROBROMIDEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT03032510Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract InfectionsPhase 31,2052019-10-02Complicated Urinary Tract InfectionsERAVACYCLINE, ERTAPENEMIts record names the diseaseClinicalTrials.gov
NCT01595529The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"Phase 27172020-07-13Urinary Tract InfectionCEFIXIME, CEPHALEXIN, TRIMETHOPRIMIts record names the diseaseClinicalTrials.gov
NCT02486627A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)Phase 36092018-08-23Complicated Urinary Tract Infection, Acute PyelonephritisMEROPENEM, PLAZOMICINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT01345929Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including PyelonephritisPhase 35582015-01-15Complicated Urinary Tract Infection, PyelonephritisCEFTOLOZANE, LEVOFLOXACIN, TAZOBACTAMOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT05630833A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)Phase 33802025-03-17Urinary Tract InfectionsGEPOTIDACINIts record names the diseaseClinicalTrials.gov
NCT01644643Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant PathogensPhase 33452015-12-14Complicated Urinary Tract Infection, Complicated Intra-abdominal InfectionAVIBACTAM, CEFTAZIDIMEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov

1 to 10 of 74

See all 74 trials

Comparisons in its trials82

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)285 of 804200 of 7981,602NCT04187144Trial comparisons
Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)5 of 8045 of 7981,602NCT04187144Trial comparisons
Gepotidacin vs Nitrofurantoin: deaths from any cause0 of 8040 of 7981,602NCT04187144Trial comparisons
Gepotidacin vs Nitrofurantoin: serious adverse events5 of 8045 of 7981,602NCT04187144Trial comparisons
Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)266 of 766165 of 7601,526NCT04020341Trial comparisons
Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)2 of 7663 of 7601,526NCT04020341Trial comparisons
Gepotidacin vs Nitrofurantoin: deaths from any cause0 of 7660 of 7601,526NCT04020341Trial comparisons
Gepotidacin vs Nitrofurantoin: serious adverse events2 of 7663 of 7601,526NCT04020341Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population176 of 685176 of 6871,372NCT03788967Trial comparisons
TBPM-PI-HBr 600 mg vs Ertapenem 1 g: deaths from any cause0 of 6850 of 6871,372NCT03788967Trial comparisons

1 to 10 of 82

See all 82 comparisons in its trials

Papers from its trials87

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
36689671RESULT1PubMed
34447992RESULT1PubMed
33191112RESULT1PubMed
32865377RESULT1PubMed
31535829RESULT1PubMed
29485006RESULT1PubMed
28914703RESULT1PubMed
28594764RESULT1PubMed
28116468RESULT1PubMed
27033958RESULT1PubMed

1 to 10 of 87

See all 87 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100338

GET https://conductscience.org/api/diseases/v1/MONDO_0100338/drugs?page=2

API referenceFor AI assistants